vs
Side-by-side financial comparison of Federal Realty Investment Trust (FRT) and Bio-Techne (TECH). Click either name above to swap in a different company.
Federal Realty Investment Trust is the larger business by last-quarter revenue ($336.0M vs $295.9M, roughly 1.1× Bio-Techne). Federal Realty Investment Trust runs the higher net margin — 38.6% vs 12.8%, a 25.8% gap on every dollar of revenue. On growth, Federal Realty Investment Trust posted the faster year-over-year revenue change (8.7% vs -6.4%). Over the past eight quarters, Federal Realty Investment Trust's revenue compounded faster (6.5% CAGR vs 4.2%).
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
FRT vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $336.0M | $295.9M |
| Net Profit | $129.7M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 53.8% | 18.4% |
| Net Margin | 38.6% | 12.8% |
| Revenue YoY | 8.7% | -6.4% |
| Net Profit YoY | 103.5% | 68.3% |
| EPS (diluted) | $1.49 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.0M | — | ||
| Q4 25 | $336.0M | $295.9M | ||
| Q3 25 | $322.3M | — | ||
| Q2 25 | $311.5M | $317.0M | ||
| Q1 25 | $309.2M | $316.2M | ||
| Q4 24 | $311.4M | $297.0M | ||
| Q3 24 | $303.6M | $289.5M | ||
| Q2 24 | $296.1M | $306.1M |
| Q1 26 | $129.7M | — | ||
| Q4 25 | $129.7M | $38.0M | ||
| Q3 25 | $61.6M | — | ||
| Q2 25 | $155.9M | $-17.7M | ||
| Q1 25 | $63.8M | $22.6M | ||
| Q4 24 | $65.5M | $34.9M | ||
| Q3 24 | $61.0M | $33.6M | ||
| Q2 24 | $112.0M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | 53.8% | — | ||
| Q4 25 | 53.8% | 18.4% | ||
| Q3 25 | 34.3% | — | ||
| Q2 25 | 65.1% | -7.5% | ||
| Q1 25 | 35.0% | 12.2% | ||
| Q4 24 | 35.1% | 16.0% | ||
| Q3 24 | 34.9% | 13.8% | ||
| Q2 24 | 53.0% | 15.0% |
| Q1 26 | 38.6% | — | ||
| Q4 25 | 38.6% | 12.8% | ||
| Q3 25 | 19.1% | — | ||
| Q2 25 | 50.0% | -5.6% | ||
| Q1 25 | 20.6% | 7.1% | ||
| Q4 24 | 21.0% | 11.7% | ||
| Q3 24 | 20.1% | 11.6% | ||
| Q2 24 | 37.8% | 13.3% |
| Q1 26 | $1.49 | — | ||
| Q4 25 | $1.49 | $0.24 | ||
| Q3 25 | $0.69 | — | ||
| Q2 25 | $1.78 | $-0.11 | ||
| Q1 25 | $0.72 | $0.14 | ||
| Q4 24 | $0.74 | $0.22 | ||
| Q3 24 | $0.70 | $0.21 | ||
| Q2 24 | $1.32 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $107.4M | $172.9M |
| Total DebtLower is stronger | $5.0B | $260.0M |
| Stockholders' EquityBook value | $3.2B | $2.0B |
| Total Assets | $9.1B | $2.5B |
| Debt / EquityLower = less leverage | 1.53× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $107.4M | — | ||
| Q4 25 | $107.4M | $172.9M | ||
| Q3 25 | $111.3M | — | ||
| Q2 25 | $177.0M | $162.2M | ||
| Q1 25 | $109.2M | $140.7M | ||
| Q4 24 | $123.4M | $177.5M | ||
| Q3 24 | $97.0M | $187.5M | ||
| Q2 24 | $103.2M | $152.9M |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $4.5B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $2.0B | ||
| Q3 25 | $3.2B | — | ||
| Q2 25 | $3.2B | $1.9B | ||
| Q1 25 | $3.2B | $2.0B | ||
| Q4 24 | $3.2B | $2.1B | ||
| Q3 24 | $3.1B | $2.1B | ||
| Q2 24 | $3.0B | $2.1B |
| Q1 26 | $9.1B | — | ||
| Q4 25 | $9.1B | $2.5B | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.6B | $2.6B | ||
| Q1 25 | $8.6B | $2.6B | ||
| Q4 24 | $8.5B | $2.7B | ||
| Q3 24 | $8.5B | $2.7B | ||
| Q2 24 | $8.4B | $2.7B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.53× | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 1.42× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRT
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
